NAMA Advocate

FDA Talk Paper April 20, 2001 T01-15 Print Media: 301-827-6242 Broadcast Media: 301-827-3434 Consumer Inquiries: 888-INFO-FDA The FDA is strengthening warnings to physicians about serious cardiac adverse events associated with Orlaam (levomethadyl acetate HC), a drug for opiate addiction treatment. FDA has changed the Orlaam labeling to increase the strength of the warnings and to…

 Chapter Websites NAMA NorCal   Gulf Coast NAMA   Maryland NAMA   TexNAMA  Chapter Forums Dolophinia Cafe   TexNAMA’s Advocate Forum   Gay Opiate Recovery  Affiliate Websites Méta dâme (Canada)   Croatian Alliance of Methadone Advocates BrugerForeningen (Danish)   The Alliance  (UK) Landelijk Steunpunt Druggebruikers (Dutch)   Sociali Gruppo (Italy) Svenska BrukarForeningen (Sweden)   INTEGRATION (Romania)   LIBERATION (Poland)   Australian IV League  

Congratulations to Sara Gefvert, the 2022 Lane/Holden Award Winner! November 2, 2022 The 2022 Richard Lane/Robert Holden Patient Advocacy Award was presented at an Awards Reception held in conjunction with the 2022 Conference of the American Association for the Treatment of Opioid Dependence (AATOD) in Baltimore, Maryland on November 2, 2022. Richard Lane/Robert Holden Patient…

National Alliance of Methadone Advocates The President’s Office Joycelyn Woods Update on Regulations Countdown to Official Date 3-year Period of Transition Begins: May 17, 2001

Journal Articles Anderson, J. Methadone, history, pharmacology, outcomes, clinical issues and future trends. Advance 2002 April: 42-48. (PDF Format) Coates, E.A.; Brennan, D.; Logan, R.M.; Goss, A.N.; Scopacasa, B.; Spencer, A.J.; Gorkic, E. Hepatitis c and associated health problems. Australian Dental Journal 2000 45(2): 108-114. (PDF Format) D’Aunno, T.; Pollack, H.A. Changes in Methadone Treatment…